We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00524732
First Posted: September 5, 2007
Last Update Posted: January 14, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )
  Purpose
To compare the reactogenicity of ADACEL® vaccine given at intervals of 2 to 9 years with the reactogenicity of ADACEL® vaccine given at an interval of 10 or more years following the last previous administration of vaccine containing Diphtheria and Tetanus Toxoids (referred to as TD/Td).

Condition Intervention
Pertussis Diphtheria Biological: Tetanus and diphtheria toxoids and acellular pertussis

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional

Resource links provided by NLM:


Further study details as provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):

Primary Outcome Measures:
  • To provide safety information on ADACEL® vaccine given at different time intervals. [ Time Frame: Up to 114 months post-vaccination ]

Enrollment: 7156
Study Start Date: September 2004
Study Completion Date: September 2005
Primary Completion Date: December 2004 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1
18 to 30 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
2
30 to 42 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
3
42 to 54 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
4
54 to 66 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
5
66 to 78 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
6
78 to 90 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
7
90 to 102 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
8
102 to 114 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®
9
Control - over 114 months since last prior dose of TD/Td vaccine.
Biological: Tetanus and diphtheria toxoids and acellular pertussis
0.5 mL, Intramuscular
Other Name: ADACEL®

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   7 Years to 19 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Children and Adolescents 7 to 19 Years of Age, who have previously recieved Tetanus and Diphtheria Toxoids Vaccine
Criteria

Inclusion Criteria:

  • Age > 7 years and < 20 years.
  • Signed and dated IRB-approved informed consent form obtained from the participant, parent or legal guardian prior to the first study intervention.
  • Judged to be in good health on the basis of reported medical history.
  • Available for planned length of the study.
  • Participant or parent or legal guardian (as applicable) can read and write English and can understand the informed consent documents and the study instructions.

A participant eleven years of age or older who meets an exclusion criterion may not be enrolled in the study but nonetheless may participate in the vaccination program, at the discretion of the Prince Edward Island public health authorities).

A participant younger than eleven years of age who meets an exclusion criterion may not be enrolled in the study and may not participate in the vaccination program.

Exclusion Criteria:

  • Known or suspected allergy to ADACEL®, any of the vaccine's components, or prior allergic reaction to Diphtheria or Tetanus Toxoids or Acellular Pertussis Vaccine.
  • Planned receipt of any other vaccine within the 14 days following administration of ADACEL® vaccine in this study.
  • Any other medical condition that in the opinion of the investigator would cause an unexpected hazard or interfere with the study objective.
  • Receipt of TD/Td within the preceding 12 months.
  • Known or suspected to be pregnant.

A participant eleven years of age or older who meets an exclusion criterion may not be enrolled in the study but nonetheless may participate in the vaccination program, at the discretion of the Prince Edward Island public health authorities).

A participant younger than eleven years of age who meets an exclusion criterion may not be enrolled in the study and may not participate in the vaccination program.

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00524732


Locations
Canada, Nova Scotia
Halifax, Nova Scotia, Canada, NS B3K 6R8
Canada
Charlottetown, Canada, C1A 7N8
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
Study Director: Medical Director Sanofi Pasteur Inc.
  More Information

Additional Information:
Publications:
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT00524732     History of Changes
Other Study ID Numbers: TD511
First Submitted: September 4, 2007
First Posted: September 5, 2007
Last Update Posted: January 14, 2014
Last Verified: January 2014

Keywords provided by Sanofi ( Sanofi Pasteur, a Sanofi Company ):
Pertussis
Tetanus
Diphtheria

Additional relevant MeSH terms:
Whooping Cough
Diphtheria
Bordetella Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Corynebacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Vaccines
Immunologic Factors
Physiological Effects of Drugs